AU1868102A - Identification of Bap-1, a protein that binds to integrin and is involved in integrin-mediated signal transduction - Google Patents

Description

444*** 4 4 t 4.

*4 4% 444%* 4.

~4 w 4.

4 4.

04 44%~ 0 *4.4

AUSTRALIA

Patents Act 1990 COR Therapeutics, Inc.

COMPLETE SPECIFICATION STANDARD PATENT Invention Title: Identification of Bap-1, a protein that binds to integrin and is involved in integrin-mediated signal transduction The following statement is a full description of this invention including the bestinethiod of perfulmmig iL 15,11uwu *4 0 444 4 44 4 0* 44 044 4 4 4 444 4 4.4. 4 4 444 4 4 *4 4 4 4444 444 44 4 44 4 4 444 4 444 *4 44 444 444 4 444 4.

44 4444 4 4 4 4. 4 444 4

-IA-

IDENTIFICATION OF Bap-1, A PROTEIN THAT BINDS TO IN17EGRIN. AND IS INVOLVED IN INTEGRI-MEDIA17ED SIGNAL TRANSDUCTION RELATED APPLICATI;ONS This application is a continuation-in-part Of application serial No. 08P-53,038, filed November 18, 1996, which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION *The present invention relates to the field of integrin-mediated signaling, particularly signal ftransduction mediated by P33 integrins such as caVI3 and aIlbj3. The invention relates specifically to the identification of a novel human gene, tentatively named Bap-1. Bap-1 encodes a protein, Bap-1, that interacts with the cytoplasmic domains of allb or P33 integrins, and Src kinase, and is involved in j3 nernmda sgnal transduction.

BACKGROUND OF THE INVENTION Integrins are a family of apj heterodimers that mediate adhesion of cells to extr-acellular matrix proteins and to other cells (Clark et aL, Science 268: 233-239, 1995).

Integrins also participate in signal transduction, as evidenced by either an alteration in adhesive affinity of cell surface integrins in response to cellular activation (termed insideout signal transduction) or by affecting intracellular signaling pathways following integrin-mediated adhesion (termed outside-in signal transduction). Many biological -2responses are dependent at least to some extent upon integrin-mediated adhesion and cell migration, including embryonic development, hemostasis, clot retraction, mitosis, angiogenesis, cell migration, inflammation, immune response, leukocyte homing and activation, phagocytosis, bone resorption, tumor growth and metastasis, atherosclerosis, restenosis, wound healing, viral infectivity, amyloid toxicity, programmed cell death and the response of cells to mechanical stress.

The integrin family consists of 15 related known a subunits (al, a2, 3 a4, a6, a7, a8, a9, aE, aV, allb, aL, aM, and aX) and 8 related known 3 subunits (p1, p2, P3, P4, p5, p6, p7, and 38). (Luscinskas et FASEB J. 8:929-938, 1994.) Integrin a 10 and p subunits are known to exist in a variety of pairings. Integrin ligand specificity is determined by the specific pairing of the a and P subunits, although some redundancy exists as several of the integrins are known to bind the same ligand. Most integrins containing the 3P1, 12, p3, p5, p6, and p7 subunits have been found to transduce signals (reviewed by Hynes, Cell 69:11-25, 1992). Integrins are involved in both "inside-out" 15 and "outside-in" signaling events.

Various pathologies associated with integrin-related defects are known. For example, inherited deficiencies of GP Ilb-ila (also termed allbp3) content or function have been described (termed Glanzmann's thrombasthenia) and are characterized by S. platelets that do not bind adhesive proteins and therefore fail to aggregate, resulting in a .9 *1 20 life-long bleeding diathesis. Inhibitors of the binding of fibrinogen and von Willebrand factor to GP IIb-m a have been described and have been found to block platelet aggregation in vitro and to inhibit clinical thrombosis in vivo (The EPIC Investigators, New England Journal ofMed 330:956-961, 1994; J.E. Tcheng et al., Circulation 91:2151-2157, 1995). Also, leukocyte adhesion deficiency (LAD) results from the absence of a p2 subunit, and is characterized by leukocytes which fail to bind p2 integrin ligands, resulting in individuals that are susceptible to infections.

9 9 -3- The most studied platelet integrin a llb3 (GPIbmla) plays a critical role in homeostasis (platelet aggregation) and also in thrombosis. The aVp3 plays a critical role in melanoma metastasis and angiogenesis, which is essential for cancer cell growth. The adhesion capacity of aElbP3 is known to be stimulated by various agonists such as thrombin, collagen, and ADP. This is termed inside-out signaling. There is accumulating evidence suggesting that integrins, in various cells and tissues including platelets, are also capable of mediating signals from the exterior to the cell interior, and that these signals 10 can trigger cellular processes such as stimulating protein tyrosine phosphorylation, activating Na+/H+ antiporter, assembly of cytoskeletal structures and regulating gene expression that is involved in cell migration and proliferation. However, the mechanisms by which these signals are transmitted remain elusive. It has been hypothesized that the cytoplasmic tails of cIbp3 and other integrins may play important roles in adhesion by modulating the ligand-binding function of the extracellular domains through responses to intracellular signals generated by agonists stimulation (inside-out), and by mediating signals triggered by integrin receptor occupancy to intracellular molecules that may play a pivotal role in cellular physiological and pathological functions (outside-in).

A. Inside-Out Sigaling Inside-out signal transduction has been observed for p1, P2, and 33 integrins.

(R-

O. Hynes, Cell 69:11-25, 1992; D. R. Phillips, et al. Cell 65:359-362, 1991, S.S. Smyth et al., Blood 81:2827-2843, 1993; M. H. Ginsberg, et al. Thromb. Haemostasis 70:87-93, 1993; R. L. Juliano and S. Haskill, J. Cell Biol. 120:577-585, 1993; E. Rouslahti, Clin.

Invest. 87:1-5, 1991; Weber et al., J. Cell Biol. 134:1063-1073, 1996.) 5 *SS SS 5 5 5 oo -4- Perhaps the most widely studied integrin that is involved in inside-out signaling is GP Ib-mIa, the receptor for four adhesive proteins, fibrinogen, von Willebrand factor, vitronectin and fibronectin that bind to stimulated platelets R. Phillips, et al., Blood 71:831-43, 1988). The binding of adhesive proteins to GP IIb-lIa is required for platelet aggregation and normal hemostasis and is also responsible for occlusive thrombosis in high shear arteries.

GP IIb-lIa is known to be involved in inside-out signal transduction because GP 10 IIb-m a on the surface of unstimulated platelets is capable of recognizing only immobilized fibrinogen. In response to platelet stimulation by agents such as thrombin, collagen and ADP, GP IIb-Ma becomes a receptor for the four adhesive proteins identified in the previous paragraph, and the binding of fibrinogen and von Willebrand factor causes platelets to aggregate. A monoclonal antibody has been described which 15 detects the activated, receptor competent state of GP IIb-la, suggesting that the conformation of the receptor competent form of GP IIb-Ma differs from that of GP lIbia which does not bind soluble fibrinogen or von Willebrand factor J. Shattil, et aL, J. Biol. Chem. 260:11107-11114, 1985). It has been postulated that inside-out GP IIb-lIa l signal transduction is dependent on cellular proteins that act to repress or stimulate GP 20 Ib-ma activation H. Ginsberg, et al., Curr. Opin. Cell Biol. 4:766-771, 1992).

P2 integrins on leukocytes also respond to inside-out signal transduction which accounts, for example, for the increased binding activity ofLFA-1 (aLP 2 on stimulated lymphocytes and the increased binding activity of MAC-1 (amp) on stimulated neutrophils (reviewed by T. Springer, Curr. Biol. 4:506-517, 1994).

55 S 5* B. Outside-In Signaling Most integrins can be involved in outside-in signal transduction as evidenced by observations showing that binding of adhesive proteins or antibodies to integrins affects the activities of many cells, for example cellular differentiation, various markers of cell activation, gene expression, and cell proliferation 0. Hynes, Cell 69:11-25, 1992).

The involvement of GP Ib-Ia in outside-in signaling is apparent because the binding of unstimulated platelets to immobilized fibrinogen, a process mediated by GP IIb-m a, leads to platelet activation and platelet spreading Kieffer and D.R Phillips, J. Cell Biol.

10 113:451-461, 1991; Haimovich et a, J. Biol. Chem. 268:15868-15877, 1993).

Outside-in signaling through GP IIb-lla also occurs during platelet aggregation.

Signaling occurs because fibrinogen or von Willebrand factor bound to the activated form of GP IIb-Mia on the surface of stimulated platelets, coupled with the formation of platelet-platelet contacts, causes further platelet stimulation through GP IIb-ma signal transduction. In this manner, binding of adhesive proteins to GP IIb-ma can both initiate .platelet stimulation or can augment stimulation induced by the other platelet agonists such *o as ADP, thrombin and collagen. The binding of soluble fibrinogen to GP -Ib-IIa on unstimulated platelets can also be induced by selected GP lIb-m a antibodies such as LIBS6 Huang et al., J. Cell Biol. 122:473-483, 1993): although platelets with 20 fibrinogen bound in this manner are not believed to be stimulated, such platelets will aggregate if agitated and will become stimulated following aggregation through GP IIbma signal transduction.

Outside-in integrin signal transduction results in the activation of one or more cascades within cells. For GP Ilb-ma, effects caused by integrin ligation include enhanced actin polymerization, increased Na/H* exchange, activation ofphospholipases, increased phosphatidyl turnover, increased cytoplasmic Ca", and activation ofkinases.

Kinases known to be activated include PKC, myosin light chain kinase, src, syk and -6- Kinase substrates identified include pleckstrin, myosin light chain, src, syk pp125FAK, and numerous proteins yet to be identified (reviewed in E. A. Clark and J. S.

Brugge, Sci. 268:233-239, 1995). Many of these signaling events, including phosphorylations, also occur in response to ligation of other integrins (reviewed in R. O.

Hynes, Cell 69:11-25, 1992). Although these other integrins have distinct sequences and distinct a-p parings that allow for ligand specificity, the highly conserved nature of the relatively small cytoplasmic domains, both between species and between subunits, predicts that related mechanisms will be responsible for the transduction mechanisms of many integrins.

C. Signal Transduction a The involvement of the cytoplasmic domain of GP HIb-ma in integrin signal Stransductions s inferred from mutagenesis experiments. Deletion of the cytoplasmic 15 domain of GP IIb results in a constitutively active receptor that binds fibrinogen with an affinity equivalent to the wild-type complex, implying that the cytoplasmic tail of GP ITb has a regulatory role E. O'Toole, et al., Cell Regul. 1:883-893, 1990). Point mutations, deletions and other truncations of GP IIb-Ela affects the ligand binding activity of GP IIb-ma and its signaling response E. Hughes, et al., J. Biol. Chem.

20 270:12411-12417, 1995; J. Ylanne, et al., J. Biol. Chem. 270:9550-9557, 1995).

Chimeric, transmembrane proteins containing the cytoplasmic domain of GP lla, but not of GP IIb, inhibit the function of GP IIb-Ma Chen et al., J Cell Biol 269:18307-18310, 1994), implying that free GP Mla cytoplasmic domains bind proteins within cells which are necessary for normal GP Ib-Ia function. Several proteins have been shown to bind either the transmembrane domains or the cytoplasmic domains of GP IIb or GP ma.

CD-9, a member of the tetraspanin family of proteins Lanza, et al., J Biol.

Chem. 266:10638-10645, 1991), has been found to interact with GP lIb-IIa on aggregated platelets. p3-endonexin, a protein identified through two hybrid screening using the cytoplasmic domain of GP Mla as the "bait", has been found to interact directly and selectively with the cytoplasmic tail of GP IIa Shattil et al., J. Cell. Biol.

131:807-816, 1995). p3-endonexin shows decreased binding to the GP Ma cytoplasmic domain containing the thrombasthenic S752-P mutation. It is not yet known whether either of these GP fIIa-binding proteins are involved in signal transduction.

Cytoplasmic proteins that bind to aVp3 have also been described which may be interacting with the integrin at the GP mla cytoplasmic domain sequence. Bartfeld and 10 coworkers S. Bartfeld et al., J. Biol. Chem. 268:17270-17276, 1993) used immunoprecipitation from detergent lysates to show that a MW=190-kDa protein associates with the aVp3 integrin from PDGF-stimulated 3T3 cells. IRS-1 was found to bind to the aVp3 integrin following insulin stimulation of Rat-1 cells stably transfected with DNA encoding the human insulin receptor Vuori and E. Ruoslahti, Sci.

266:1576-1578, 1994). Kolanus et al. (Cell 86:233-242, 1996) recently identified Cytohesin-1. Cytohesin-1 specifically binds to the intracellular portion of the integrin 32 chain, and overexpression of cytohesin-1 induces p2 integrin-dependent binding of Jurkat cells to ICAM-1. A novel serine/threonine kinase, ILK-1, was found to associate with the 31 cytoplasmic domain (Hannigan et al., Nature 379:91-96, 1996). Overexpression of ILK-1 inhibits adhesion to the integrin ligands fibronectin, laminin, and vitronectin.

Integrin binding to adhesive proteins and integrin signal transduction have a wide variety of physiological roles, as identified above. Enhanced signaling through integrins allows for increased cell adhesion and activation of intracellular signaling molecules which causes enhanced cell mobility and growth, enhanced cell responsiveness, and modulations in morphological transformations. Although integrins responsible for cellular function have been described and signaling events are beginning to be elucidated, the mechanism by which integrins transduce signals remains to be determined.

0 0.0 *S -8- To understand the molecular mechanisms of the inside-out and outside-in signaling roles mediated by the cytoplasmic tails of P3 integrin requires the identification of the intracellular molecules that interact with the intracellular tails ofintegrin. It has been reported that a-actinin binds to P 31 tails in vitro (Otey et al. J Biol. Chem.

268:21193-21197, 1993) but the functional relevance of these bindings is not clear. By using yeast two-hybrid, ILK-I was identified as a PI31 interacting protein but ILK-1 does not bind to 33 (Hannigan et al., Nature 379:91-96 (1996). The present invention describes the molecular cloning of a novel human gene, Bap-1, encoding a protein, Bap-1, that associates with the integrin subunit an and 33 cytoplasmic tails. Bap-I was also 10 found to associate with Src kinase. The molecular isolation of Bap-1 forms the basis for the development of therapeutic agents that modulate integrin-mediated signal transduction.

*000 *0

*D

y*

*I.

.000 0 a. (0 *0 '000 0 0 000 0*S*e* 0 000 0 0 0 0 00 *0 0 0 000 0 0** 0e 0e 0** 00* 0 0** 0* 0 0** 0 00 0 oo0 0 *e -9- SUMMARY OF THE INVENTION The present invention is based, in part, on the isolation and identification of a protein that binds to the cytoplasmic domain of the p3 subunit of integrins, hereinafter Bap-1 or the Bap-1 protein. Bap-1 was subsequently demonstrated to associate with the cytoplasmic domain of the calb subunit and Src kinase. Based on this observation, the present invention provides purified Bap-1 protein, useful in a variety of ways because of such associations.

S' 10 The present invention further provides nucleic acid molecules that encode the f Bap-1 protein. Such nucleic acid molecules can be in an isolated form, or can be operably linked to expression control elements or vector sequences.

The present invention further provides methods of identifying other members of the Bap-1 and/or Bap family of proteins. Specifically, the nucleic acid sequence of Bap-I can be used as a probe, or to generate PCR primers, in methods to identify nucleic acid molecules that encode other members of the Bap-1 or Bap family of proteins.

The present invention further provides antibodies that bind to Bap-1. Such antibodies can be either polyclonal or monoclonal. Anti-Bap-1 antibodies can be used in a variety of diagnostic formats and for a variety of therapeutic methods.

0 The present invention further provides methods for reducing or blocking the association of an integrin with a cytoplasmic signaling partner. Specifically, the association of an integrin with a cytoplasmic signaling partner, such as Bap-1 or a Bap-1/signaling partner complex, Bap-1/Src kinase, can be blocked or reduced by contacting an integrin having a 33 or allb subunit with an agent that blocks the binding of Bap-1 or the Bap-1/signaling partner complex to the integrin. The method can utilize an agent that binds to the cytopiasmic domain of the iniegrin or an agent that binds to Bap'or the Bap-1/signaling partner complex such as the Bap-1/Src complex.

*9 9 o* 9 9g99 9 9 9 9 9 9 9 99 9 9 9 99 9 99 9o• Blocking integrin/Bap-1 associations can be used to modulate biological and pathological processes that require integrin mediated signals. Such methods and agents can be used to modulate cellular attachment or adhesion to a substrate or another cell, cellular migration, cellular proliferation and cellular differentiation. Pathological processes involving these actions include thrombosis, inflammation, tumor metastasis, wound healing and others noted above.

The present invention further provides methods for isolating integrin signaling 10 partners that bind to Bap-1 or to a Bap-1/p3 complex. Integrin signaling partners are isolated using the Bap-1 protein or the Bap-1/p3 complex as a capture probe.

Specifically, the Bap-1 protein, or a fragment thereof or the Bap-1/p3 complex, is mixed with an extract prepared from an integrin expressing cell under conditions that allow association of the Bap-1 protein, fragment, or complex with a signaling partner. Non- 15 associated cellular constituents are removed from the mixture and the signaling partner is released from the capture probe. Alternatively, Bap-1 can be used as bait in the yeast *two-hybrid system to screen an expression library and identify genes that encode proteins with the ability to bind to Bap-1 protein. Signaling partners isolated by these methods are I useful in preparing antibodies and also serve as targets for drug development 20 The present invention further provides methods to identify agents that can block or modulate the association of an integrin with Bap-1 or a signaling complex.

Specifically, an agent can be tested for the ability to block, reduce or otherwise modulate the association of an integrin with Bap-l or a signaling complex by incubating the Bap-1 protein, or a fragment thereof with a P3 integrin and a test agent and determining whether the test agent blocks or reduces the binding of the Bap-1 protein to the $3 integrin.

Agonists, antagonists and other modulators expressly are contemplated.

0: 0 0 0 S0,09 0 :00 0. 0 0. 0 00 -11- The biological and pathological processes that require Bap-1/integrin interaction can further be modulated using gene therapy methods. Additional genetic manipulation within an organism can be used to alter the expression of aBap-1 gene or the production of a Bap-1 protein in an animal model. For example, a Bap-1-gene can be introduced into an individual deficient for Bap-1 to correct a genetic deficiency; peptide modulators of Bap-1 activity can be produced within a target cell using genetic transformation methods to introduce a modulator encoding nucleic acid molecules into a target cell; and Bap-1 can be inactivated in a non-human mammal to produce animal models of Bap-1 deficiency.

The latter application, Bap-1-deficient animals, is particularly useful for identifying 10 agents that modulate Bap-1 activity and other genes that encode proteins that interact with Bap-1. The use of nucleic acids for antisense and triple helix therapies and interventions are expressly contemplated.

The present invention further provides methods of reducing the severity of pathological processes that require integrin mediated signaling. Since association of Bap-1 or Bap-1 complex with a p3 integrin is required for integrin-mediated signaling, agents that block integrin/Bap-1 association can be used in therapeutic methods.

BRIEF DESCRIPTION OF THE DRAWINGS 20 Figs. 1A-1B show the nucleic acid sequence of human Bap-1 and the amino acid sequence of human Bap-1.

Figs. 2A-2B show a partial nucleic acid of mouse Bap-1 and the amino acid sequence of mouse Bap-1.

_t f nr-ta Cfoo Rn-/ Fig. 3 shows Udeletion .mutants produc of .flatg- taged-- r .0 o o. 0,0 -12-

I

.1.11.

0S S 33S*.

U. *S *r* Fig. 4 summarizes the effects of the expression of full-length or deletion mutant, flag-tagged Bap-1 on the expression ofa NF-kB-CAT fusion.

Fig. 5 summarizes the effects of the expression of full-length or deletion mutant, flag-tagged Bap-1 on the expression of an AP-l-CAT fusion.

V Oa a a a

S

-13- DETAILED DESCRIPTION OF THE PREFERRED

EMBODIMENT

I. General Description The present invention is based in part on identifying a protein that binds to P3 integrins and is involved in integrin-mediated signaling, hereinafter the Bap-1 protein.

Bap-1 is also found to associate with the cytoplasmic tail of llb and Src kinase.

The Bap-1 protein can be used as an agent, or serve as a target for agents, that can be used to inhibit integrin mediated signaling, for example to inhibit biological processes requiring GP HIb-ma or aVp3 signal transduction.

10 The present invention is further based on the development of methods for isolating proteins that bind to Bap-1 or a Bap-l/P3 or Bap-1/Src kinase complex. Probes based on the Bap-1 protein are used as capture probes to isolate Bap-1/integrin-associated signaling proteins. Dominant negative proteins, DNAs encoding these proteins, antibodies to these signaling proteins, peptide fragments of these proteins or mimics of these proteins may be introduced into cells to affect integrin function. Additionally, these proteins provide a novel target for screening of synthetic small molecules and combinatorial or naturally occurring compound libraries to discover novel therapeutics to regulate integrin function.

o S 5* 5 *S S S e 0* -14- II. Specific Embodiments A. Bap-1 Protein The present invention provides isolated Bap-1 protein, as well as allelic variantsof the Bap-1 protein, and conservative amino acid substitutions of the Bap-1 protein. As used herein, the Bap-1 protein (or Bap-1) refers to a protein that has the amino acid sequence of human Bap-1 depicted in Figure 1. The Bap-1 protein includes naturally occurring allelic variants of Bap-1, proteins that have a slightly different amino acid sequence than that specifically recited above. Allelic variants, though possessing a 10 slightly different amino acid sequence than those recited above, will still have the ~requisite ability to associate with a p3 integrin as part of the relevant signaling cascade.

.As used herein, the Bap-1 family of proteins refers to Bap-1 proteins that have c isolated from organisms in addition to humans. One such member of the Bap-1 family of proteins is the mouse Bap-1 protein whose partial amino acid and nucleotide sequence is 15 depicted in Figure 2. The methods used to identify and isolate other members of the Bap-1 family of proteins are described below and in Example As used herein, the Bap family of proteins refers to proteins that bind to P3 integrins, are structurally related to Bap-1, containing significant sequence homology to S. l Bap-1. Members of the Bap family of proteins are involved in integrin-mediated 0. :tt; 20 signaling. For convenience, the Bap-1 protein, members of the Bap-1 family of proteins, and members of the Bap family of proteins are hereinafter referred to as the Bap proteins of the present invention.

The Bap proteins of the present invention are preferably in isolated form. As used herein, a protein is said to be isolated when physical, mechanical or chemical methods are employed to remove the Bap protein from cellular constituents that are normally associated with the Bap protein. A skilled artisan can readily employ standard purification methods to obtain an isolated Bap protein.

0. 0 *0 0 0 S V 0 0: 00 0 05 S OS S 0 55 S *5 0 0 060 0 0 5 5 The Bap proteins of the present invention further include conservative variants of the Bap proteins herein described. As used herein, a conservative variant refers to alterations in the amino acid sequence that do not adversely affect the ability of the Bap protein to bind to a P3 integrin and mediate signaling. A substitution, insertion or deletion is said to adversely affect the Bap protein when the altered sequence prevents the Bap protein from associating with a P3 integrin. For example, the overall charge, structure or hydrophobic/hydrophilic properties of Bap can be altered without adversely affecting activity of Bap. Accordingly, the amino acid sequence of Bap can be altered, for example to render the peptide more hydrophobic or hydrophilic, without adversely 10 affecting the ability of the peptide to become associated with a 33 protegrin.

Ordinarily, the allelic variants, the conservative substitution variants, the members of the Bap family of proteins and especially the members of the Bap-1 family of proteins, will have an amino acid sequence having at least 75% amino acid sequence identity with the human or mouse Bap-1 sequence, more preferably at least 80%, even more preferably 15 at least 90%, and most preferably at least 95%. Identity or homology with respect to such sequences is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the known peptides, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not Sconsidering any conservative substitutions as part of the sequence identity. N-terminal, C-terminal or internal extensions, deletions, or insertions into the peptide sequence shall not be construed as affecting homology.

Thus, the Bap proteins of the present invention include molecules having the amino acid sequences disclosed in Figure 1; fragments thereof having a consecutive sequence of at least about 3, 5, 10 or 15 amino acid residues of the Bap-1 protein; amino acid sequence variants of such sequence wherein an amino acid residue has been inserted N- or C-terminal to, or within, the disclosed Bap-1 squcncC; amino acid sequence variants of the disclosed Bap-1 sequence, or their fragments as defined above, that have 99• o 9 9 9 9 9 9 999 -16-

S.

S.

S

S..

S.

S

*5*S been substituted by another residue. Contemplated variants further include those containing predetermined mutations by, homologous recombination, site-directed or PCR mutagenesis, and the corresponding Bap proteins of other animal species, including but not limited to rabbit, rat, murine, porcine, bovine, ovine, equine and non-human primate species, and the alleles or other naturally occurring variants of the Bap family of proteins; and derivatives wherein the Bap protein has been covalently modified by substitution, chemical, enzymatic, or other appropriate means with a moiety other than a naturally occurring amino acid (for example a detectable moiety such as an enzyme or radioisotope).

As described below, members of the Bap family of proteins can be used: 1) to identify and isolate other integrin signaling partners that bind Bap-1 or a Bap-1/3 complex, 2) in methods to identify agents that block the association of an integrin with Bap-1 or a Bap-l/signaling complex, 3) as a target to assay for integrin mediated signaling, and 4) as a therapeutic agent to block the association of an integrin with Bap-1 or a Bap-1/signaling complex.

S S S *S* S S 55 *5 S S S 5 55 5 *S S S 55 5 S 55 5 5 555 S S

S

S.

S

*a: S S

S..

-17- B. Bap-1 Encoding Nucleic Acid Molecules The present invention further provides nucleic acid molecules that encode Bap-1, and the related Bap proteins herein described, preferably in isolated form. As used herein, "nucleic acid" is defined as RNA or DNA that encodes a peptide as defined above, or is complementary to nucleic acid sequence encoding such peptides, or hybridizes to such nucleic acid and remains stably bound to it under appropriate stringency conditions, or encodes a polypeptide sharing at least 75% sequence identity, preferably at least 80%, and 10 more preferably at least 85%, with the peptide sequences. Specifically contemplated are genomic DNA, cDNA, mRNA and antisense molecules, as well as nucleic acids based on alternative backbone or including alternative bases whether derived from natural sources or synthesized. Such hybridizing or complementary nucleic acid, however, is defined further as being novel and unobvious over any prior art nucleic acid including that which S. 15 encodes, hybridizes under appropriate stringency conditions, or is complementary to nucleic acid encoding a Bap protein according to the present invention.

"Stringent conditions" are those that employ low ionic strength and high temperature for washing, for example, 0.015M NaCI/0.0015M sodium titrate/0.1% SDS at 50 0 or employ during hybridization a denaturing agent such as formamide, for 20 example, 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% S. polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaC1, mM sodium citrate at 42 0 C. Another example is use of 50% formamide, 5 x SSC (0.75M ::NaCI, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 Tg/ml), 0.1% SDS, and 10% dextran sulfate at 42 0 with washes at 42 0 C. in 0.2 x SSC and 0.1% SDS. A skilled artisan can readily determine and vary the stringency conditions appropriately to obtain a clear and detectable hybridization signal.

99.o 99 9 99 99 9 9 9 99• 9 9 99 9 9 9 9 9 999 9 18- As used herein, a nucleic acid molecule is said to be "isolated" when the nucleic acid molecule is substantially separated from contaminant nucleic acid encoding other polypeptides from the source of nucleic acid.

The present invention further provides fragments of the Bap encoding nucleic acid molecule. As used herein, a fragment of a Bap encoding nucleic acid molecule refers to a small portion of the entire protein encoding sequence. The size of the fragment will be determined by the intended use. For example, if the fragment is chosen so as to encode an active portion of the Bap protein, the fragment will need to be large enough to encode the functional region(s) of the Bap protein. If the fragment is to be used as a nucleic acid probe or 10 PCR primer, then the fragment length is chosen so as to obtain a relatively small number of S. *false positives during probing/priming. If the fragment is chosen so as to bind the p3 integrin, the length will be chosen so as to contain the p3 contact site on the Bap protein.

S. Fragments of the Bap encoding nucleic acid molecules of the present invention (Le., f synthetic oligonucleotides) that are used as probes or specific primers for the polymerase 15 chain reaction (PCR), or to synthesize gene sequences encoding Bap-1 proteins can easily be synthesized by chemical techniques, for example, the phosphotriester method ofMatteucci, et Am. Chem. Soc. 103:3185-3191, 1981) orusing automated synthesis methods. In addition, larger DNA segments can readily be prepared by well known methods, such as synthesis of a group of oligonucleotides that define various modular segments of the Bap 20 gene, followed by ligation of oligonucleotides to build the complete modified Bap gene.

The Bap encoding nucleic acid molecules of the present invention may further be modified so as to contain a detectable label for diagnostic and probe purposes. A variety of such labels are known in the art and can readily be employed with the Bap encoding Smolecules herein described. Suitable labels include, but are not limited to, biotin, radiolabeled nucleotides and the like. A skilled artisan can employ any of the art known labels to obtain a labeled Bap encoding nucleic acid molecule.

Modifications to the primary structure itself by deletion, addition, or alteration of the 99 9 9 999 99 9 99 99 9~ 99 9 9 9 9 9 9 9 99 9 19amino acids incorporated into the protein sequence during translation can be made without destroying the activity of the protein. Such substitutions or other alterations result in proteins having an amino acid sequence encoded by DNA falling within the contexnplated scope of the present invention.

0 00 0 0 0 0 0 0 C. Isolation of Other Bap Encoding Nucleic Acid Molecules As described above, the identification of the human and mouse Bap-1 encoding nucleic acid molecules allows a skilled artisan to isolate nucleic acid molecules that encode other members of the Bap-1 family of proteins in addition to the human and mouse sequence herein described. Further, the presently disclosed nucleic acid molecules allow a skilled artisan to isolate nucleic acid molecules that encode other members of the Bap family of proteins in addition to Bap-1.

10 Essentially, a skilled artisan can readily use the amino acid sequence ofBap-1 to S. generate antibody probes to screen expression libraries prepared from cells involved in integrin signaling. Typically, polyclonal antiserum from mammals such as rabbits immunized with the purified Bap-1 protein (as described below) or monoclonal antibodies can be used to probe a mammalian cDNA or genomic expression library, such as lambda gtll S 15 hibrary, to obtain the appropriate coding sequence for Bap-1, or other members of the Bap family of proteins. The cloned cDNA sequence can be expressed as a fusion protein, expressed directly using its own control sequences, or expressed by constructions using control sequences appropriate to the particular host used for expression of the enzyme. Figure 1 identifies important antigenic and/or putative operative domains found in the Bap-1 protein 20 sequence. Such regions are preferred sources of antigenic portions of the Bap-1 protein for the production of probe, diagnostic, and therapeutic antibodies.

Alternatively, a portion of the Bap-1 encoding sequence herein described can be synthesized and used as a probe to retrieve DNA encoding Bap-l families of proteins from any mammalian organisms that possess integrin-mediated signaling pathways. Oligomers containing approximately 18-20 nucleotides (encoding about a 6-7 amino acid stretch) are prepared and used to screen genomic DNA or cDNA libraries to obtain hybridization under stringent conditions or conditions of sufficient stringency to eliminate an undue level of false -21 positives.

Additionally, pairs of oligonucleotide primers can be prepared for use in a polymerase chain reaction (PCR) to selectively clone a Bap-encoding nucleic acid molecule. -A POR denature/anneal/exted cycle for using such POR primers is well known in the art and canreadily be adapted for use in isolating other Bap encoding nucleic acid molecules. Figure 1 identifies regions of the human Bap-1 gene thiat are particularly well suited for use as a probe or as primers.

0e 9.

9.

4* a 0 Or

S

S

S

S

S

S

S. *S*

S

-22- D. rDNA molecules Containing a Bap Encoding Nucleic Acid Molecule The present invention further provides recombinant DNA molecules (rDNAs) that contain a Bap encoding sequence. As used herein, a rDNA molecule is a DNA molecule that has been subjected to molecular manipulation in situ. Methods for generating rDNA molecules are well known in the art, for example, see Sambrook et aL. Molecular Cloning (1989). In the preferred rDNA molecules, a Bap encoding DNA sequence is operably linked to expression control sequences and/or vector sequences.

10 The choice of vector and/or expression control sequences to which one of the Bap encoding sequences of the present invention is operably linked depends directly, as is well known in the art, on the functional properties desired, protein expression, and the host cell to be transformed. A vector contemplated by the present invention is at least capable of f directing the replication or insertion into the host chromosome, and preferably also expression, 15 of the Bap structural gene included in the rDNA molecule.

Expression control elements that are used for regulating the expression of an operably linked protein encoding sequence are known in the art and include, but are not limited to, inducible promoters, constitutive promoters, secretion signals, and other regulatory elements.

.Preferably, the inducible promoter is readily controlled, such as being responsive to a nutrient 20 in the host cell's medium.

In one embodiment, the vector containing a Bap encoding nucleic acid molecule will include a prokaryotic replicon, a DNA sequence having the ability to direct autonomous replication and maintenance of the recombinant DNA molecule extrachromosomally in a prokaryotic host cell, such as a bacterial host cell, transformed therewith. Such replicons are well known in the art In addition, vectors that include a prokaryotic replicon may also include a gene whose expression confers a detectable marker such as a dnrg resistance Typical bacterial drug resistance genes are those that confer resistance to ampicillin or 23 tetracycline.

Vectors that include a prokaryotic replicon can further include a prokaryotic or viral promoter capable of directing the expression (transcription and translation) of the Bap encoding gene sequences in a bacterial host cell, such as E. coli. A promoter is an expression control element formed by a DNA sequence that permits binding ofRNA polymerase and transcription to occur. Promoter sequences compatible with bacterial hosts are typically provided in plasmid vectors containing convenient restriction sites for insertion of a DNA .segment of the present invention. Typical of such vector plasmids are pUC8, pUC9, pBR322 and pBR329 available from Biorad Laboratories, (Richmond, CA), pPL and pKK223 10 available from Pharmacia, Piscataway,

NJ.

SExpression vectors compatible with eukaryotic cells, preferably those compatible with :vertebrate cells, can also be used to form a rDNA molecules the contains a Bap encoding sequence. Eukaryotic cell expression vectors are well known in the art and are available from several commercial sources. Typically, such vectors are provided containing convenient 66 15 restriction sites for insertion of the desired DNA segment. Typical of such vectors are PSVL Sand pKSV-10 (Pharmacia), pBPV-/pML2d (International Biotechnologies, Inc.), pTDT1 i (ATCC, #31255), the vector pCDM8 described herein, and the like eukaryotic expression vectors.

Eukaryotic cell expression vectors used to construct the rDNA molecules of the present invention may further include a selectable marker that is effective in aa eukaryotic cell preferably a drug resistance selection marker. A preferred drug resistance marker is the gene whose expression results in neomycin resistance, ie., the neomycin phosphotransferase '(neo) gene. (Southern et aL, J Mo. Anal. Genet. 1327-341, 1982.) Alternatively, the selectable marker can be present on a separate plasmid, and the two vectors are introduced by co-transfection of the host cell, and selected by culturing in the appropriate drug for the selectable marker.

Or 6666 6 -24- E Host Ceils Containing an Exogenously Supplied Bap Encoding Nucleic Acdd Molecule The present invention further provides host cells transformed with a nucleic acid molecule that encodes a Bap protein of the present invention. The host cell can be either prokaryotic or eukaryotic. Eukaryotic cells useful for expression of a Bap-lI protein are not liieso long as the cell line is compatible with cell culture mehd and comatible with~ the propagation of the expression vector and expression of the Bap-! gene product prefened Goo**:eukaryotic host cells include, but are not limited to, yeast, insect and nianimalian cells, 0* preferab~ly vertebrate cells such as those from a mouse, r-4 monkey or human firoblasi cel 10 line. Prefened eukaryotic host cells include Chinese hamster ovary (CHO) cells available from the ATCC as CCL6l, N]H Swiss mouse embryo cells NIH3T available from the ATCC as CRL 1658, baby hamster kidney cells (B3HK), and the like eukaryotic tissue culture cell lines.

Any prokaryotic host can be used to express a Bap-encoding rDNA molecule. The preferred prokaryotic host is E. coft.

0 ~Transformation of appropriate cell hosts with a rIDNA molecule of thle present invention is accomplished by well known methods that typically depend on the type of vector *.:used and host system employed. With regard to transformation of prokaryotic host cells, electroporation and salt treatment methods are typically employed, see, for example, Cohen et' aL, Pro- Nad ACad SU U&A 69:2110,1l 9 7 2; and Manatis eaL, Moecuar oning. A Laboraory Mammal Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982). With regard to transformation of vertebrate cells with vectors containing rDNAs, electroporation, cationic lipid or salt treatment methods are typically employed, see, for example, Graham et al, Virol 52:456, 1973; Wvigler et aL, Proc. NatL AcaiL SL USA 76:1373-76, 1979.

Successfully transformed cells, cells that contain a rDNA molecule of the present invention, can be identified by well known techniques. For examplie. cells resulting fr-om the introduction of an rDNA of the present invention can be cloned to produce single colonies.

00.. .0 so.. 'e *5 0 0 0 0 V5 0,0 00 Cells from those colonies can be harvested, lysed and their DNA content examined for the presence of the rDNA using a method such as that described by Southern, J MoL BioL 98:503, 1975, or Berent et dL, Mioteclz 3:208, 1985 or the proteins produced from the cell assayed via an immunological method.

*.eeee

S

eq ~e 0 Ge See.

0e S 0

C.

S

e e.

.ID 96.0.

e De. 0.OS 0e C

*S

0~ 0**e 9 S .e Ce*e 0*Ie a,

C'

Ce ~e

C

.09 0* C e eec~00 to 4% 0 S* e.

0 0 t o C 05 o 0. S C 0 Se eec 0 e C. ece eec 9 -26- F. Production of Bap using a rDNA molecule encoding a Rap Protein The present invention further provides methods for producing a Hap protein that uses one of the Hap encoding nucleic acid molecules herein described. In general terms, the production of a recombinant forn of a Bap protein typically involves the following steps: First, a nucleic acid molecule is obtained that encodes a Bap protein, such as the nucleic acid molecule depicted in Figure If the Bap encoding sequence is uninterrupted by.

introns, it is directly suitable for expression in any host.

The Hap encoding nucleic acid molecule is then preferably placed in operable linkage with suitable control sequences, as described above, to form an expression unit containing the 6 Hap encoding sequences. The expression unit is used to transform a suitable host and the C64*00,transformed host is cultured under conditions that allow the production of the Hap protein.

I::::Optionally the Hap- I protein is isolated from the mediumn or from the cells; recovery and purification of the protein may not be necessary in some instances where some impurities may be tolerated.

a Each of the foregoing steps can be done in a variety of ways. For example, the desired coding sequences may be obtained from genonic, fragments anid used directly in appropriate hosts. The construction of expression vectors that are operable in a variety of hosts is Accomplished using appropriate replicons and control sequences, as set forth above. The control sequences, expression vectors, and transformation methods are dependent on the type of host cell used to express the gene and were discussed in detail earlier. Suitable restriction :sites can, if not normally available, be added to the ends of the coding sequence so as to 00 provide an excisable gene to insert into these vectors. A skilled artisan can readily adapt any host/expression system known in the art for use with Hap encoding sequences to produce Hap protein.

-27- G. Methods to Identify Other Integrin Signaling Partners Another embodiment of the present invention provides methods for use in isolating and identifying cytoplasmic signaling partners ofintegrins. Specifically, the Bap protein alone, or in combination with an integrin containing a p3 subunit (hereinafter a Bap/p3 complex), can be used to identify signaling partners that bind Bap or Bap/33 complex from cells that express integrins.

In detail, a Bap protein alone, or in combination with an integrin containing a P3 subunit or Bap/p3 complex, is mixed with an extract or fraction of a cell that expresses an integrin under conditions that allow the association of a signaling partner with the Bap or 10 Bap/p3 complex. After mixing, peptides that have become associated with Bap-1 or the Bap-I/p3 complex are separated from the mixture. The signaling partner that bound Bap-1 or the Bap-1/p3 complex can then be removed and further analyzed.

To identify and isolate a signaling partner, the entire Bap protein can be used.

Alternatively, a fragment of a Bap protein can be used.

15 As used herein, a cellular extract refers to a preparation or fraction which is made from a lysed or disrupted cell. The preferred source of cellular extracts will be cells which naturally express p3 integrins. Examples of such cells include, but are not limited to platelets and leukocytes.

A variety of methods can be used to obtain an extract of a cell. Cells can be 20 disrupted using either physical or chemical disruption methods. Examples of physical disruption methods include, but are not limited to, sonication and mechanical shearing.

Examples of chemical lysis methods include, but are not limited to, detergent lysis and the enzyme lysis. A skilled artisan can readily adapt methods for preparing cellular extracts in order to obtain extracts for use in the present methods.

The cellular extract can be prepared from cells that have been freshly isolated from a subject or from cells or cell lines which have been cultured. In addition, the extract can be prepared from cells that are either in a resting state or from cells that have -28been activated. A variety of agents can be used to activate a celL The selection of an activating agent will be based on the cell type used. For example, thrombin, collagen or ADP can be used to activate platelets while PMA can be used to activate leukocytes.

Once an extract of a cell is prepared, the extract is mixed with the Bap protein, or a Bap/p3 complex, under conditions in which association of the Bap or Bap/P3 complex with the signaling partner can occur. A variety of conditions can be used, the most preferred being conditions that closely resemble conditions found in the cytoplasm of an integrin-expressing cell. Features such as osmolarity, pH, temperature, and the concentration of cellular extract used, can be varied to optimize the association of the 10 integrin with the signaling partner.

After mixing under appropriate conditions, Bap or the Bap/p3 complex is separated from the mixture. A variety of techniques can be utilized to separate the mixture. For example, antibodies specific to Bap or the Bap/p3 complex can be used to immunoprecipitate the Bap or Bap/p3 complex and associated signaling partner.

Alternatively, standard chemical separation techniques such as chromatography and density/sediment centrifugation can be used.

*After removal ofnonassociated cellular constituents found in the extract, the signaling partner can be dissociated from the Bap or Bap/p3 complex using conventional methods. For example, dissociation can be accomplished by altering the salt concentration or pH of the mixture.

To aid in separating associated integrin/signaling partner pairs from the mixed extract, the Bap or Bap/P3 complex can be immobilized on a solid support. For example, Bap can be attached to a nitrocellulose matrix or acrylic beads. Attachment of Bap to a solid support aids in separating peptide/signaling partner pair from other constituents found in the extract The identified signaling partners can be either a single protein or a complex made up of two or more proteins.

S S S S S S *S S S S 5 S 555 -29- Alternatively, the Bap-encoding nucleic acid molecule can be used in a yeast two-.

hybrid system. The yeast two-hybrid system has been used to identify other protein partner pairs and can readily be adapted to employ the Bap encoding molecules herein described. (See Example 2.) *te a a a a a a a a. a..

a a a a a a a a a..

a a a a a a a a a a.

a a a a. a. *a.

.a a a **s

S

a.

a *5 H. Use of Bap and Other Isolated Signaling Partners Once isolated, the integrin Signaling partners obtained using the above described method, as well as the Bap proteins herein described, especially Bap-1, can be used for a variety of purposes. These proteins can be used to generate antibodies that, bind to the Bap protein, or the signaling partner, using techniques known in the art Antibodies that bind Bap or another integrin signaling partner can be used to assay integrin signalin& as a therapeutic agent to modulate a biological or pathological process mediated by integrin signaling, or to purify the signaling partner. These uses are described in detail below.

-31- I. Methods to Identify Agents that Block Integrin Cytoplasmic Signaling Partner Interactions Another embodiment of the present invention provides methods for identifying agents that reduce or block the association of an integrin with a cytoplasmic signaling complex, such as a Bap protein or a Bap/signaling partner complex, hereinafter collectively referred to as Bap signaling complex. Specifically, a p3 integrin is mixed with a Bap protein, a cellular extract containing Bap, or a complex of Bap and the signaling partner described above, in the presence and absence of an agent to be tested.

After mixing under conditions that allow association of the integrin or peptide with the Bap signaling complex, the two mixtures are analyzed and compared to determine if the *agent reduced or blocked the association of the integrin with the Bap signaling complex.

Agents that block or reduce the association of an integrin with the Bap signaling complex will be identified as decreasing the amount of association present in the sample containing the tested agent.

In an alternative format, agents that block or reduce the transcriptional repressor activity of Bap-1 can be isolated by using fusions between the transcriptional control elements of genes whose expression levels are repressed by Bap-1 and reporter genes such as CAT (chloramphenicol acetyl transferase). Examples of such fusions include NFkB-CAT, and AP-1-CAT fusions. In this format, cells which express the appropriate 20 reporter fusion are transfected to express Bap-1 in the presence and absence of the agent to be tested. Cell lines which exhibit a reduced ability of Bap-1 to repress the expression of the reporter gene in the presence of the agent being tested, identify agents which are i capable of inhibiting Bap-1 repressor activity. Assays to detect reporter gene expression are widely and commercially available as are numerous reporter genes, including but not limited to CAT and P-galactosidase (P-gal) For instance, such assays are commercially available from GIBCO-BRL.

As used herein, an agent is said to reduce or block integrin/Bap signaling complex •0 04' 00 0. 0.0•• -32association when the presence of the agent decreases the extent to which or prevents the Bap signaling complex from becoming associated with the p3 integrin. One class of agents will reduce or block the association by binding to the Bap signaling complex while another class of agents will reduce or block the association by binding to the p3 integrin.

The Bap signaling complex used in the above assay can either be an isolated and fully characterized protein, such as Bap-1, or can be a partially characterized protein that binds to Bap-1 or a Bap- /signaling partner complex that has been identified as being present in a cellular extract It will be apparent to one of ordinary skill in the art that so long as the Bap signaling complex has been characterized by an identifiable property, 10 molecular weight, the present assay can be used.

Agents that are assayed in the above method can be randomly selected or rationally selected or designed. As used herein, an agent is said to be randomly selected when the agent is chosen randomly without considering the specific sequences involved S in the association of the integrin with the Bap signaling complex. An example of 15 randomly selected agents is the use a chemical library or a peptide combinatorial library, or a growth broth of an organism.

As used herein, an agent is said to be rationally selected or designed when the agent is chosen on a nonrandom basis which takes into account the sequence of the target site and/or its conformation in connection with the agent's action. As described above, 20 there are two sites of action for agents that block integrin/Bap signaling complex interaction: the cytoplasmic domain of the p3 subunit or the Bap signaling complex.

Agents can be rationally selected or rationally designed by utilizing the peptide sequences that make up the contact sites of the integrin/Bap signaling complex pair. For example, a S. rationally selected peptide agent can be a peptide whose amino acid sequence is identical to the Bap-1 contact site on the cytoplasmic domain of the integrin or the 13 contact site on Bap-1. Such an agent will reduce or block the association of the integrin with the signaling partner by binding to Bap-1 or the p3 integrin respectively.

S* .00 0 0 000 000 S 0 0 0 60 0& 0 0 -33- The agents of the present invention can be, as examples, peptides, small molecules, vitamin derivatives, as well as carbohydrates. A skilled artisan can readily recognize that there is no limit as to the structural nature of the agents of the present invention.

One class of agents of the present invention are peptide agents whose amino acid sequences are chosen based on the amino acid sequence of the cytoplasmic domain of the P3 subunit or the amino acid sequence of the Bap protein, such as the human Bap-1 sequence depicted in Figure 1.

The peptide agents of the invention can be prepared using standard solid phase (or solution phase) peptide synthesis methods, as is known in the art. In addition, the DNA encoding these peptides may be synthesized using commercially available oligonucleotide synthesis instrumentation and produced recombinantly using standard recombinant production systems. The production using solid phase peptide synthesis is necessitated if non-gene-encoded amino acids are to be included.

15 Another class of agents of the present invention are antibodies immunoreactive with critical positions of the cytoplasmic domain of an integrin or with a Bap signaling complex such as Bap-1. Antibody agents are obtained by immunization of suitable mammalian subjects with peptides, containing as antigenic regions, those portions of the *3 cytoplasmic domain or Bap signaling complex, intended to be targeted by the 20 antibodies. Critical regions include the contact sites involved in the association of the integrin with the Bap signaling complex.

Antibody agents are prepared by immunizing suitable mammalian hosts in appropriate immunization protocols using the peptide haptens alone, if they are of sufficient length, or, if desired, or if required to enhance immunogenicity, conjugated to suitable carriers. Methods for preparing immunogenic conjugates with carriers such as BSA, KLH, or other carrier proteins are well known in the art. In some circumstances, direct conjugation using, for example, carbodiimide reagents may be effective; in other -34instances linking reagents such as those supplied by Pierce Chemical Co., Rockford, IL, may be desirable to provide accessibility to the hapten. The hapten peptides can be extended at either the amino or carboxy terminus with a Cys residue or interspersed with cysteine residues, for example, to facilitate linking to a carrier. Administration of the immunogens is conducted generally by injection over a suitable time period and with use of suitable adjuvants, as is generally understood in the art. During the immunization schedule, titers of antibodies are taken to determine adequacy of antibody formation.

While the polyclonal antisera produced in this way may be satisfactory for some 0applications, for pharmaceutical compositions, use of monoclonal preparations is 10 preferred. Immortalized cell lines which secrete the desired monoclonal antibodies may be prepared using the standard method of Kohler and Milstein or modifications which effect immortalization of lymphocytes or spleen cells, as is generally known. The immortalized cell lines secreting the desired antibodies are screened by immunoassay in which the antigen is the peptide hapten or is the integrin or signaling complex itself.

s oWhen the appropriate immortalized cell culture secreting the desired antibody is 0*0o*0 identified, the cells can be cultured either in viro or by production in ascites fluid.

"0 :'"The desired monoclonal antibodies are then recovered from the culture 00 supernatant or from the ascites supernatant. Fragments of the monoclonals or the 0000 polyclonal antisera which contain the immunologically significant portion can be used as 20 antagonists, as well as the intact antibodies. Use of immunologically reactive fragments, such as the Fab, Fab', of F(ab) 2 fragments is often preferable, especially in a therapeutic context, as these fragments are generally less immunogenic than the whole "0 immunoglobulin.

The antibodies or fragments may also be produced, using current technology, by recombinant means. Regions that bind specifically to the desired regions of receptor can also be produced in the context nfrnhimeas t ir; 1ip... i-.

The antibodies thus produced are useful not only as modulators of the association 0 0 0. 0: 0, 000 000• 00 0000 0000 000 35 of an integrin with a Bap signaling complex, but are also useful in immunoassays for detecting integrin mediated signaling and for the purification of integrin-associated signaling proteins.

000000 0 00 0 0 00 0 0 0000 0* 0 0 00 0000..

0 *00000 0 0 0 000 *0 00 0 0 0 otO 00000* 0 000000 .0 00 O 00 0000 0 0000 00 0 00 0 0.00

O

*0,0 00 00 00 0.0 0 0 00 0 *0 0 00 00 0 0'0. 0 .00 0 0 00 *0 0. 0.0 0 0 0 0 0 0 000 0 00 0 00 00 000 0 0 *0 a S -36- J. Uses for Agents that Block the Association of an Integrin with a Bap Signaling Complex As provided in the Background section, integrins play important roles in intracellular signaling, cellular attachment, cellular aggregation and cellular migration.

Agents that reduce or block the interactions of an integrin with a Bap signaling complex can be used to modulate biological and pathologic processes associated with integrin function and activity.

In detail, a biological or pathological process mediated by an integrin can be 10 modulated by administering to a subject an agent that blocks the interaction of an integrin with a Bap signaling complex.

As used herein, a subject can be any mammal, so long as the mammal is in need of modulation of a pathological or biological process mediated by an integrin. The term "mammal" is meant an individual belonging to the class Mammalia. The invention is particularly useful in the treatment of human subjects.

As used herein, a biological or pathological process mediated by an integrin or *0 integrin signaling refers to the wide variety of cellular events in which an integrin binds a substrate producing an intracellular signal that involves the Bap protein or a Bap signaling complex. Examples of biological processes include, but are not limited to, cellular 20 attachment or adhesion to substrates and other cells, cellular aggregation, cellular migration, cell proliferation, and cell differentiation.

Pathological processes refer to a category of biological processes which produce a deleterious effect For example, thrombosis is the deleterious attachment and aggregation of platelets while metastasis is the deleterious migration and proliferation of tumor cells.

These pathological processes can be modulated using agents which reduce or block integrin/Bap signaling complex association.

As used herein, an agent is said to modulate a pathological process when the agent 9 9 0 0 9 -37reduces the degree or severity of the process. For example, an agent is said to modulate thrombosis when the agent reduces the attachment or aggregation of platelets.

Two known parings of the P33 subunit have been observed: with aV to make aV33, the Vitronectin Receptor, and with GP Ilb to make GP Hb-Illa, the Fibrinogen Receptor. aVf33 is widely distributed, is the most promiscuous member of the integrin family and mediates cellular attachment to a wide spectrum of adhesive proteins, mostly at the R-G-D sequence on the adhesive protein. The biological processes mediated by .VP3 are diverse and include bone resorption, angiogenesis, tumor metastasis and restenosis. aV33 is known to signal upon adhesive protein ligation Leavesley, et al., J. Cell Biol. 121:163-170, 1993). As an example, endothelial cells undergo apoptosis when relieved of ligation Brooks, Cell 79:1157-1164, 1994).

•GP fIb-ma, by contrast, is restricted to platelets and cells of megakaryocyte lineage although a report has appeared indicating that GP lib-mIa is present in tumor cell ,F lineages. As discussed in detail elsewhere in this application, the function of GP ib-lila 15 is primarily to bind adhesive proteins to mediate platelet aggregation. In this function, GP Ilb-ifia participates in both inside-out and outside-in signaling. Decreased receptor function of GP Ilb-Ifla leads to bleeding;, elevated receptor function of GP Ub-ifia can lead to thrombus formation. Studies have appeared indicating that platelet aggregation 0 •o""through GP fib-llMa may also be involved in tumor metastasis.

o* a a a o* a a a a a a a.aa a o. ao a -38- K. Administration of Agents that Affect Integrin Signaling The agents of the present invention can be provided alone, or in combination with another agents that modulate a particular pathological process. For example, an agent of the present invention that reduces thrombosis by blocking integrin mediated cellular signaling can be administered in combination with other anti-thrombotic agents. As used herein, two agents are said to be administered in combination when the two agents are -administered simultaneously or are administered independently in a fashion such that the agents will act at the same time.

The agents of the present invention can be administered via parenteral, 10 subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, or buccal routes.

Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.

The present invention further provides compositions containing one or more agents which block integrin/signaling complex association. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typical dosages comprise 0.1 to 100 Tg/kg bodywt. The preferred dosages comprise 0.1 to 10 Tg/kg body wt The most preferred dosages comprise 0.1 to 1 Tg/kg body wt.

20 In addition to the pharmacologically active agent, the compositions of the present invention may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically for delivery to the site of action.

Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, 0 05 0 0 5 0 0 0 -39sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides.

Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers. Liposomes can also be used to encapsulate the agent for delivery into the cell.

The pharmaceutical formulation for systemic administration according to the invention may be formulated for enteral, parenteral or topical administration. Indeed, all three types of formulations may be used simultaneously to achieve systemic administration of the active ingredient

C.

10 Suitable formulations for oral administration include hard or soft gelatin capsules, pills, tablets, including coated tablets, elixirs, suspensions, syrups or inhalations and controlled release forms thereof.

In practicing the methods of this invention, the compounds of this invention may be used alone or in combination, or in combination with other therapeutic or diagnostic 15 agents. In certain preferred embodiments, the compounds of this invention may be coadministered along with other compounds typically prescribed for these conditions according to generally accepted medical practice, such as anticoagulant agents, thrombolytic agents, or other antithrombotics, including platelet aggregation inhibitors, tissue plasminogen activators, urokinase, prourokinase, streptokinase, heparin, aspirin, or 20 warfarin. The compounds of this invention can be utilized in vivo, ordinarily in mammals, such as humans, sheep, horses, cattle, pigs, dogs, cats, rats and mice, or in vitro.

COO

C 0 0 d C C L. Methods for Identifying Integrin-Mediated Signaling The present invention further provides methods for identifying cells involved in integrin-mediated signaling as well as techniques that can be applied to diagnose biological and pathological processes associated with integrin-mediated signaling.

Specifically, integrin-mediated signaling can be identified by determining whether the Bap protein, or Bap signaling complex, is expressed and/or is associated with a 33 integrin. Cells expressing Bap or the Bap signaling complex, or in which Bap or the Bap e* signaling complex is associated with a 33 integrin are considered to be involved in integrin-mediated signaling. Such methods are useful in identifying sites of 10 inflammation, thrombosis, angiogenesis and tumor metastasis.

In one example, an extract of cells is prepared which contains the p3 integrin. The extract is then assayed to determine whether the p3 integrin is associated with Bap or a Bap signaling complex. The degree of association present provides a measurement of the degree of signaling the cell is participating in. An increase in the degree of signaling is a i 15 measurement of the level of integrin mediated activity.

For example, to determine whether a tumor has metastatic potential, an extract is made of the tumor cells and the p3 integrins expressed by the tumor cells are isolated using known methods such as immunoprecipitation. The integrins are then analyzed, for example, by gel electrophoresis to determine whether a Bap protein is associated with the 20 integrin. The presence and level of a Bap association correlates with the metastatic potential of the cancer.

Alternatively, the level of Bap protein or Bap gene expression can be used to directly correlate with the involvement of the cell in integrin-mediated signaling. A variety of immunological and nucleic acid techniques can be used to determine if the Bap protein, or a Bap encoding mRNA, is produced in a particular cell. The presence of increased levels of the Bap protein or the Bap encoding mRNA correlates with the I %L ,x JaL U L'UUUII L'LNA, correlates wlt dL metastatic potential of the cancer.

o o•• -41- M. Gene Therapy The Bap gene and the Bap protein can also serve as a target for gene therapy in a variety of contexts. For example, in one application, Bap-deficient non-human animals can be generated using standard knock-out procedures to inactivate a Bap gene. In such a use, a non-human mammal, for example a mouse or a rat, is generated in which a member of the Bap family of genes is inactivated. This can be accomplished using a variety of artknown procedures such as targeted recombination. Once generated, the Bap-deficient animal can be used to 1) identify biological and pathological processes mediated by Bap, 2) identify proteins and other genes that interact with Bap, 3) identify agents that can be 10 exogenously supplied to overcome Bap deficiency and 4) serve as an appropriate screen for identifying mutations within Bap that increase or decrease activity.

In addition to animal models, human Bap-deficiency can be corrected by supplying to a human, a genetic construct that encodes the Bap protein which is deficient in the subject. A variety of techniques are presently available, and others are being 15 developed, for introducing a nucleic acid molecule into a human subject to correct a genetic deficiency. Such methods can be readily adapted to employ the Bap-encoding nucleic acid molecules of the present invention.

2. In another embodiment, genetic therapy can be used as a means for modulating a Bap-mediated biological or pathological processes. For example, during graft rejection, it 20 may be desirable to introduce into the subject being treated a genetic expression unit that encodes a modulator of Bap-1/integrin mediated signaling, such as an antisense encoding nucleic acid molecule. Such a modulator can either be constitutively produced or inducible within a cell or specific target cell. This allows a continual or inducible supply of a therapeutic agent within the subject.

As set forth in the Examples, Bap-1 appears to be a transcriptional repressor that targets genes including those regulated by NF-kB and AP-1. Since both AP-1 and NF-kB are involved in many types of disease such as cancers, the Bap-1 gene itself may serve as 42 a therapeutic agent for the treatment of diseases related to gene up-regulation.

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilise the compounds of the present invention and practice the claimed methods. The following working examples therefore, specifically point out preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

Other generic configurations will be apparent to one skilled in the art.

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base :or were common general knowledge in the field relevant to the present invention as it existed in Australia before the priority date of each claim of this application.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a 2: stated element, integer or step, or group of elements, integers or steps, but not 20 the exclusion of any other element, integer or step, or group of elements, integers or steps.

a 0 0 oa o a a a a a a a a y -43-

EXAMPLES

Example 1 Cloning of Bap-1 A yeast two-hybrid system (Chien et aL, Proc. Natl. Acad. Sci. USA 88:9578- 9582, 1991) was used to identify proteins that interact specifically with the cytoplasmic *tail of the p3 integrin subunit The histidine selection system (Durfee et al., Genes. Dev.

7:555-569, 1993), which utilizes two distinct GAL4-dependent reporter genes, HIS3 and 10 lacZ was employed. The bait was the P3 cytoplasmic domain fused to the GAL4 DNA .binding domain of vector pGBT9. The new construct was designated as pGBT9-IIIa.

9*999* Approximately 5x10s primary transformants of mouse embryo cDNA library expressed as fusion products with the VP16 activation domain (Vojtek et al., Cell. 74:205-214, 1993) 4* were screened. Several hundreds clones showed significant histidine prototrophy and of 15 these 20 were strongly P-galactosidase positive. For two of these clones(126-2 and 141- S" 1) histidine prototrophy and P-galactosidase activity depended on the presence of both o :9 plasmids. As a further control, segregants containing the cDNA library plasmids only were mated with cells expressing GAL4 DNA binding protein only (pGBT9) and several tester GAL4 DNA binding protein fusions including v-Raf and mutant v-Raf (Li et al., 20 EMBO 14:685-696, 1995). Histidine prototrophy and P-galactosidase activity were ~recovered only in combination with original pGBT9-IIIa.

The cDNA library plasmid DNA of 126-2 and 141-1 were transformed into E. coli and subjected to DNA sequencing. The sequence data showed that the inserts of these two clones are from one single gene, and a search of the GenBank database revealed that this gene is not represented in the database. DNA sequencing showed that neither of the LcDNI clones cntainL a complete protein coding region. To clone the fuii-iengih cDNA of the 126-2 human homologue, a human bone marrow 50-stretch plus I gtl 1 cDNA 9 -44library (Glontech, CAT IHLSOO5b) were screened using a 400 bp Noid fr-agment isolatedj from clone 126-2 as probe. Approximately 5x10 5 clones were screened and two positive clones, gt5 and gt6, were identified. The two clones were amplified using standard techniques. DNA were prepared and the inserts were subcloned into pBSKSL cut at the Not[ site. The clone containing the NotI fragment from gt5 was designated p]BSgt5, and the clone containing the NotI insert firom phage gt6 was designated pBSgt6. Restiction mlapping and preliminary sequencing indicated that pBSgt6 has an insert of 3.5 kbp, and pBSgt5 has an insert of 2.1 kbp, contained within pBSgt6. The eDNA insert of the pBSgt6 was subjected to sequencing analysis, and was shown to have a size of 3.5 kbp 10 containing an open reading frame.

3% 3* 3* 3

S

S

S. S. S S S S S S S S S S S

S

S

S

S

*SS S .0 -0 0.0S Example 2 Bap-l Interacts with tzllb and v-Src Kinase in the Yeast Two-Hlybrid System A spectrum of proteins of the integrin family or mutants, and some potential signaling molecules, were tested for their ability to interact with Bap-1 in the yeast twohybrid system.L Bap-l was demonstrated to interact with the cytoplasmnic tail of ixflb and v-Src tyrosine kinase, but not with the cytoplasmic tail of P2, P3(S752P) serine to proline mutant, or a P3431I chimera. Further, Bap-lI was seen to interact with Bap-l in the twohybrid, suggesting that aunctional homodimer may be formed within cells. The results indicate that Bap-1I might link integrin IllbP3 signal transduction by bridging other known signaling molecules such as pp60src kinase. Src kinase, a major platelet tyrosine kinase, is speculated to be involved in tyrosine-specific phosphotylation of cellular proteins during platelet activation by different agonists Src kinase was shown to phosphorylate the P33 integrin in vitro (Law et aL,JI BioL Chem 271:10811-10815, 1996). 40% of total platelet pp60src becomes associated with the cytoskeletal fraction upon platelet activation (Horvath eta!., EMBO J1 11:855-861, 1992). Thromnbin stimulation of platelets induces a transient increase in the specific activity of ~followed by a redistribution of pp60csrc to the triton X-100-insoluble, cytoskeleton-rich .:20 fr-action (Clark et AL, Molec. Cell BioL 13:1863-1871, 1993). This association requires platelet aggregation and actin polymerization (Oda et J BioL Chem. 267:20075- **20081, 1992). The present findings implicate Bap-1 as involved in both outside-in and inside-out signaling by bridging integrins with protein tyrosine kinases.

0 0 *0 *0 -46- Example 3 Analysis of Mouse Ba-- Rap-i encodes a protein of 336 amino acids with a RING finlger domain. Analysis of the protein sequence of the Bap-1 identifies an unusual amino-terminal RING finger motif that can be written as CX2CXJ 1ECLHXFCX2CXI ICX2. The proteins thiat share a *sees:RING domain have been reported to be implicated during development, such as DG17 *(Driscoll and Williams, MCB 7:4482-4489, 1987) and Posterior Sex Combs and 10 Suppressor two of zeste (Brunk etat., Nature 353:351-353, 1991; Lohuizen et Nature 9 353:353-355, 1991), gene transcription such as R.PT-1I (Patarca, et Proc. Natl. AcacL 9 Sci. 85:2733-2737, 1988), DNA repair such as RAD-i 1(Jones et al, Nudleic Acids Res.

7119-7131, 1988), oncogenic transformation such as BMLI-l (Haupt et al, Cell 65:753-763, 199 tumor suppression such as BRCA-1I (Mfild et al., Science 266: 66-7 1, 15 1994), and signal transduction such as CD4O-binding protein (CD40-bp) (Hlu et al., J.

Bio. Chem 269:30069-30072, 1994) and TRAF2 (Raothe et Cell 78:681-692, 1994; beer aHsu et Cell 84:299-308, 1996). The solution structure of the RING finger domain from the acute promyclocyte leukemia pro-oncoprotein PML suggested that the PMLff RING finger is involved in making protein-protein interactions (Borden et al, 1995.

S. 20 EMLBO J. 14:1532-1541), a molecular mechanism which is commonly used in signaling protein complexes.

Rap-i has significant sequence similarity with the ringi gene, iLe., it has 48% .identity with PINVGJ gene at amino acid level, the fuinction of which is not known.

S S..Interestingly, Rap-i shares 17% identity with Drosophila gene Posterior Sex Combs (Psc) that is believed to be homologous to oncogene bmi-1, that was originally found to be involved in B- and T- cell lymphoma. Psc is a member of the Polycomb-group gene family, which is required to maintain the repression of homeotic genes that regulate the S S 5 S.*a: S V -47identities of Drosophila segments. bmi-1 appeared to play a similar role in vertebrates: bmi-1 knock-out mice shows posterior transformations of the axial skeleton (van der Lugt et al., Genes Dev. 8: 757-769, 1994); and overexpression of bmi-1 in mice shows the opposite phenotype, a dose-dependent anterior transformation of vertebral identity (Aldema et al, Nature 374:724-727, 1995). Both the Psc and bmi-1 can repress activator function when transiently introduced into cells (Bunker and Kingston, Molec. Cell BioL 14: 1721-1732, 1994). Furthermore mel-18, another Polycomb group-related mammalian gene which shares an amino acid sequence including RING-finger motif, can function as a transcriptional negative regulator with tumor suppressor activity.

10 All this suggests that the Bap-1 protein may play an important role in cell migration, cell proliferation, and development, for which the role of integrins is implicated. For example, the Bap-1 protein may function as a latent transcriptional .regulator, either positive or negative, that is inactive when bound to the 33 cytoplasmic tail ofintegrins, but can be activated by outside-in or inside-out signaling and then 15 dissociates from the tail and translocates into the nucleus.

.e *o* *o Or 4 0: 0. 0" r 0 -48- Example 4 Bap-I Exhibits Transcriptional Repressor Activity To determine the effects of Bap-1 expression on the transcriptional control of Ap- 1 and NF-kB dependent promoters, flag-tagged, full length bap-l as well as deletion mutants of bap- were transfected into NIH3T3 cells containing CAT fusions to Ap-1 and NF-kB dependent transcriptional control elements. Bruder et al. (1992) Genes Dev., 6, 10 545-556, and Baldwin et al. (1991) Mol. Cell Biol., 11, 4943-4951. Deletion mutants of bap-1 including the encoded amino acids are set forth in Figure 3.

Figure 4 summarizes the effects of the expression of full length and deletion mutants of bap-1 on the expression of the NF-kB-CAT reporter fusion in NIH3T3 cells.

NIH3T3 cells were grown in 100 mm dishes to 70% confluence in DMEM with 10% calf *15 serum and transfected with plasmid DNA (10 Ag/dish each ofpCIneoBap-1 or its deletion mutant, together with 4 sg/dish of reporter plasmids, pMHC-NF-KB-CAT or pB4X) using LipofectAMINE (GIBCO-BRL), following manufacturer's instruction. 24 hours after transfection, cells were washed twice with PBS; DMEM with 0.25% calf serum was added and incubated for additional 12 hours. Cells were then trypsinized and resuspended 20 in DMEM containing 0.25% calf serum and overlayed on 0.7% agarose. After cells were incubated as such for 6 hours at 37*C in a CO incubator, half of the cells were transferred to dishes coated with vitronectin at 5 ,tg/ml (for Adhesion) and half of the cells remained in the 0.7% agar (for suspension). After 90 minutes, cells were harvested and CAT ELISA assays were performed according to vendor's instruction (Boehringer Mannheim, cat #1363727). Expression of full-length Bap-l results in a slight decrease in the expression of the NF-kB-CAT fusizon. Deltio of te RIc NG domain from Bap-i results in an apparent inability of Bap-l to exhibit transcriptional repression of the NF- *0 S -49kB-CAT fusion. Deletion of the C-terminal end ofBap- results in the strong transcriptional suppression of the NF-kB-CAT fusion. These results suggest that Bap-1 RING domain is involved in repression activity, and that the C-terminal half of the protein is involved in negatively regulating the repressor activity.

Figure 5 summarizes the effects of the expression of full length and deletion mutants of bap-1 on the expression of the AP-1-CAT reporter fusion in NIH3T3 cells.

Cell culture and transfections were done as above. Expression of full-length Bap-1 results in a slight decrease in the expression of the AP-1-CAT fusion. Deletion of the RING domain from Bap-1 results in an apparent decreased ability of Bap-1 to exhibit 10 transcriptional repression of the AP-1-CAT fusion. Deletion of the C-terminal end of Bap-1 results in the strong transcriptional suppression of the AP-1-CAT fusion. These o o ~results suggest that full-length Bap-1 is involved in inhibiting AP-1 reporter activity.

Since the wild-type Bap-1 appears to be ineffective in regulating NF-KB, this suggests that wild-type Bap-1 may specifically regulating cerzain genes. Since the RING deletion 15 demonstrates repressor activity, although impaired, this suggests that in the protein there .is a second region that is involved in repressor activity. Consistent with the data obtained with the NF-kB reporter, the C-terminal half of the protein is involved in regulating the 99 repressor activity. Deletion of the C-terminal half of the protein will render the protein constitutively active.

9 6.9 r 9 9 Example Tissue distribution of Bap- The tissue distribution of Bap-1 expression was examined by Northern blot, and it was found that Bap-1 is expressed in most tissues, consistent with a suggestion that Bap-1 has an important role in cellular functions. In addition to the 3.6 kb mRNA, we detected .a 2.4 kb size mRNA in most tissues, which might be a spliced form of Bap-1, or a Bap- 10 related gene.

Clone 126-2, the partial cDNA of the mouse homologue ofBap-1, was located in 'o the central part of the Bap-1, and is 98% identical with Bap-1. Again, the high degree of conservation suggest a fundamental role for Bap-1 in cellular regulation.

Interaction between Bap-1 and the cytoplasmic tail observed in the yeast two- 15 hybrid is unlikely to be mediated by a yeast protein. This was further demonstrated by an in vitro binding assay using purified acrIb3 and purified Bap-1 protein. Specifically, Bap-1 was expressed as a GST-Bap-1 fusion protein in E. coli, and purified and immobilized on glutathione agarose beads. The immobilized GST-Bap-1 fusion was then incubated with purified cllbp3, and retention on the beads was analyzed by SDS-PAGE and Western Blotting. The results showed that (3 protein binds specifically to GST- Bap-1, but not to GST controls. The ability to confirm the binding between Bap-1 and the P3 cytoplasmic tail in vitro is consistent with the robust interaction observed in the yeast two-hybrid system.

9 999999 9 9d 99 9 99 9 9 99 9 9 9 99 9 99 999 -51- Example 6 Expression of Bap-1 in a Heterologous System CHO cells expressing allb3, like in platelets, manifest highly regulated changes in the ligand binding affinity as measured by PAC-1 binding. The CHO cell heterologous system facilitated the analysis of recombinant gene functions in the role of regulating the alIlb3 affinity. An example of this type of analysis is that CHO cells expressing aclbp3 were shown to be activated by recombinant R-Ras. (Zhang et Cell 85:61-69, 1996) To look at the effects of Bap-1 on the regulation of alIbp3, allbp3 is co-expressed with 10 the Bap-1 proteins, and deletion variants of Bap-1, and the cellular phenotypes are examined accordingly.

Two different strategies can be used to reduce endogenous Bap-1 activity/production; namely using an antisense Bap-1 molecule or using an inhibitory mutant of Bap-1. The RING domain in the TRAF2 and PML proteins have been 15 implicated as involving protein-protein interactions. In the case of TRAF2, the RING deletion mutant functions as a dominant-negative inhibitor ofTNF-mediated NF-kB activation (Cell 84:299-308). Accordingly, RING deletion may block or activate Bap-1 oo depending on the nature of the molecules that associate with the Bap-1 RING domains.

To this end, Bap-1 and variants thereof, have been flag-tagged and inserted into i 20 mammalian expression vectors. Stable cell lines that express the wild-type Bap-1, Bap-1 variants (such as the RING deletion mutant Bap-1), the Bap-1 anti-sense RNA, and the vector control can be generated using standard transformation methods. The expression ofBap-1 can be determined by anti-flag and anti-Bap-1 antibodies. The cell lines can then be examined for the effect on the activation of allbp3 (PAC-1 binding), cell spreading, and attachment on fibrinogen. Over-expression of a signaling molecule such as Bap-1 can desensitize the regulatory pathway. Therefore, transient and/or coiditional expression can also be exploited to characterize the functions of the Bap-1 gene.

-52- Example 7 Effects of Bap-1 on the aVp3 Functions on Melanoma Since the expression of Bap-i is not restricted to alrbP3 expressing cells such as platelets, Bap-1 is likely to be involved in the aVB3 functions. To this end, Bap-i and variants thereof can be transfected into an aVP3 expressing cell line such as M21 melanoma. Again, the adhesive properties such as attachment and spreading on vitronectin can be examined. The expression of aVB3 in M21 melanoma is essential for metastasis.

C

C.

C.

SC*

C C

C

C C 0 I CS

S

S

S

S

OISS

C

*5 C S .C S

C

S

4, OS@ C S C .50

J

0500.S C S CC S C SOCO 60* CC I C. C 6 0 C CC. C 59 .55 5 SO C S

CC

me.. m e.

S *5e -53- Example- 8 The Cellular Localization of Bap- *e t St.

S

Se..

*5* Ses 5.* *5

S

S

The cellular localization of Bap can be examined by in sit immunohistochelistry. Anti-Bap-1 monoclonal antibodies, particularly antibodies generated against 1) a GST-Bap-l fusion protein expressed and purified in E. coli, 2) a 26mer N-terminal peptide corresponding to a unique region of Bap-1 protein, and/or 3) a 10 26mer peptide corresponding to the central part of the protein can be readily generated and used in the inimunohistochemical examnination of Bap-1 production/expression. The tissue distribution of Bap-1 can be examined using these Bap-1I antibodies.

555 S 5 5 S

S

S S S S *SSS 55 *5 S

S

S S

S

S S S S

S*.

*S *SSS S S *SS S -54 Examiple 9 Bap-lf3interaction Tn Vivo 9 9* 9 9* 9* 9 9* 9.

9 9 9.

9* 9 9

E

*9 ~e .9 9 9* 9 9 *9 9w.. .9 9.9 t~ 999* 99*9 9 9.

9 9 *99 .9.9 99 99 .9e9 99.9 9 9 9 9 To confirm the interaction observed in the yeast two-hybrid system described above and in vitro, anti-Bap- I antibodies can be used to immunoprecipitate Bap-lI and SDS-PAGE can be used for further purification. Then the presence of P33 can be detected.

by Western blotting using anti-P3 antibodies. The reverse experiment can also be 10 performed by inimunoprecipitating P3 and blotting with anti-flag or anti-Bap-1 antibodies.

999 9 9 9 999 9 9 999999 9 9..

999999 9 9 99 9 9 99 9 9 9 99 9999 99 9 99 999 9 9 9 9. 9 9 9 9 999 9 99 9 9 9 9 9 9 9 9 99 999 9 9 .9.

9 55 Ex=Ie Identific-ation of the Domains and Amino Acids that are Critical for-Protein-Protein IntrQDto The critical residues both in the P3 tail. and in the Bap-l protein can be further identified by deletion and mutagenesis analysis. In one application, these experiments are.

done in a heterologous cell using the yeast two-hybrid system described above.

S S

S.

S.

S S

S.

S

S.

S.

55 S

S.

S

5.

S.

5055 S.

S

*00* *5* 50

S

5'* S 55

S.

S S S. S S

S.

5 5 S5* 5 555555 S 5 S *5 5 *5 S 5 S 55 S 5 5 S 5 5 S S S S S S S S *S S S S -56ooo*o«

S

S.

S.

o *5

SS

S.

S

*g *o *5 *r* oooo oo- Example 11 Cloning of Bap-I Related Genes by PCR or Library Screening A messenger RNA of 2.4 kb in size, in addition to the 3.5 kb Bap-1 mRNA, was observed in most tissues examined by Northern blot using the human Bap-1 cDNA or the mouse partial eDNA as probe. These results suggested that there are Bap-i1 related genes or spliced forms expressed. The Bap-I related genes can be readily isolated using Bap-1 cDNA as probe to screen cDNA libraries, genomic libraries, or can be used to design 10 primers based on the Bap-1 DNA sequence. The isolated genes can then be examined for their functions in integrin signaling as detailed in the other examples listed in this application.

Genomic studies of Bap-1 gene: The human chromosomal Bap-1 gene can be isolated by conventional approaches, and its genomic structure and chromosome location can be determined. A genomic database can be searched to determine if its chromosome location corresponds to any disease locus.

*S

S S 55 S S

S.

S S S 555 555 SSS S S SSSS* S S 55 5 5 5555 SSS 55 5 55 5 S S 5S5

S

555 55 555 *S S 5 S S 5 5 5 S S 5 5 555 57 Example 12 Oncogenic or Tumor Suppresor Activity of Bap- I d.

Oncogenic transformation is often accompanied by deregulation of integrin signaling, such as an increase or decrease of cell adhesion. It is interesting to note that Bap-1 has amino acid similarity to proto-oncogene Bnii-l and tumor suppressor gene Mel- 18. Accordingly, the oncogenic or tumor suppressor activity of Bap-1 can be tested.

Briefly, Bap-1 and its variants are transfected into Rat-i or NIH3T3 cells, and soft agar 10 growth and focus formation are scored, both of which are indicative of oncogenic activity.

To test tumor suppressor activity of Rap-i, Rap-i and its variants are co-transfected with a series of known oncogenes into Rat-i or NMHT3 cells, and the effects of Bap-l on the oncogenic transformation of known oncogenes are examined.

Tumor metastasis requires angiogenesis, and integrin mVP3 is essential for angiogenesis. By blocking zVP3 signaling such as by modulating Bap-l/P3 interaction, tumor metastasis can be inhibited.

a.

9 a a. a a a a a -58 Example 13 Generation of Bap-I Homozy~ous Deficient Mice I. 9.

9 *9 9

S

9. 5*

S.

.9 .9 *5~e .9.

999 99*.

*99* 9,.

a '.9.9 .9 a. .9 .9.9 *9 9*9 9* Routine genetic procedures can be used to create genetic knock-out mutants of mice in which Bap-1 has been inactivated. The preferred method is to introduce, using targeted homologous recombination, a nucleic acid molecule that contains multiple stop codons in each reading frame. This serves to inactivate the Bap-1 locus. Such mice can 10 be used to further study biochemical and physiological effects of Bap-1.

Although the present invention has been described in detail with reference to examples above, it is understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims. All cited patents and publications referred to in this application are 15 herein incorporated by reference in their entirety.

999 9 999999 9 9 9 9 o* 9 9. 9 9 9* 9e 9 1 9 9 9 o o9 °9 9

Claims (21)

1. An isolated nucleic acid molecule that encodes the amino acid sequence depicted in Figure 1, and the allelic variants of the amino acid sequence.

2. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule is operably linked to one or more expression control elements. 999999 9

9. 9 9* .r. 4 99 9 9 99 9* 00. 99 9 9 9 9 *0 *0 0 9 .9 0e 999 9 .99. 0. 9099 9 99 9S 99 9s *999 99 *r 9 3. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule is included in a vector. 4. An isolated nucleic acid molecule that encodes a member of the Bap-1 family of proteins, wherein said nucleic acid molecule hybridizes to a nucleic acid molecule of claim 1 under conditions of sufficient stringency to produce a clear signal An isolated nucleic acid molecule that encodes a member of the Bap family of proteins, wherein said nucleic acid molecule hybridizes to a nucleic acid molecule of claim 1 under conditions of sufficient stringency to produce a clear signal. *9 9 999 9 9 9 9 9 99 9 9 9 9 9* 9 9 9 9 9 999 9 6. A host transformned to contain the nucleic acid molecule of claim 1. 7. The host of claim 6, wherein said host is selected from the group consisting of prokaryotic hosts and cukaryotic hosts. 8. A method for producing a B ap-lI protein comprising the step of culturing a host ftransformed with the nucleic acid molecule of claim 2 under conditions in which the Bap-I protein is expressed. 9. The method of claim 8, wherein said host is selected from the group consisting of prokaryotic hosts and eukaryotic hosts. 0 04 0. 0 4* 4 *4 04. 4 04 0 *00 4. 0 0 6 An isolated protein comprising the amino acid sequence depicted in Figure 1. 0,0 0 4 4 .0 4 44. 40 40 40 4. 0.4 4. 44 44 444 4 4 4 4 44 4 .4. 444 4 -61

11. An isolated antibody that binds to the protein of claim

12. The antibody of claim I11 wherein said antibody is a monoclonal and polyclonal, antibody. **Geee. *d *q S S. I.

13. A method for blocking the interaction of a protein selected from the group consisting of allb, Src kinase, and a P3 integrin, with a Bap signaling complex 10 comprising the step of contacting said protein with an agent that blocks the binding of the Bap protein or a Bap signaling complex to said protein.

14. The method of claim 13 wherein said agent blocks the binding of said protein to said Bap or said Bap signaling complex by selectively binding to the cytoplasmic domain of a P3 integrin.

15. The method of claim 14 wherein said agent is a fragment of the Bap 20 protein. S. 0 0 0 0* 000 000 0 62

16. The method of claim 13 wherein said agent blocks the binding of said protein to said Bap or said Bap signaling complex by selectively binding to the Bap protein.

17. .,the Bap protein. The method of claim 16 wherein said agent is an antibody that binds 0 0..9 0 so.4 004

18. The method of claim 13 wherein said blocking reduces cellular aggregation of an integrin expressing cell.

19. The method of claimn 13 wherein said blocking reduces cellular attachment of an integrin expressing cell. The method of claim 13 wherein said blocking reduces cellular migration of an integrin expressing cell.

21. A method for reducing the severity of a pathological state mediated by integrin signaling comprising the step of contacting a P33 integrin with an agent that bloc~k the- binding of the- 1Rnrr~, ^r a D~ s o itg- Se 0 4 0'. 4.4 49 0. 444 4 44* 44 4 44 4444 444 4 44 444 4 4 4 44 4 4 44 444 4444 444 4 444 4 -63-

22. The method of claim 21 wherein said pathological state is selected from the group consisting of thrombosis, inflammation and tumor metastasis.

23. A method for identifying agents that block the interaction of a protein selected from the group consisting of allb, Src kinase and a 33 integrin with a Bap protein or Bap signaling complex comprising the steps of: a) incubating a p3 integrin, a P3 subunit of said integrin, Src kinase, or allb with Sa Bap protein or a Bap signaling complex and an agent to be tested, and 10 b) determining whether said agent blocks the binding of the Bap protein or Bap complex to said 33 integrin, said 33 subunit, said Src kinase, or said allb. 0

24. The method of claim 23 wherein said Bap protein or said Bap signaling complex is contained in an extract of a cell. A method to assay for integrin mediated signaling comprising the step of determining whether a Bap protein is expressed.

26. The method of claim 25 further comprising the steps of; a) preparing an extract of a cell, and b) examining the proteins of said cell extract to determine the presence of a Bap protein. o 0*5

27. The method of claim 25 further comprising the steps of: a) preparing an extract of a cell, and b) examining the mRNA of said cell extract to determine the presence of a Bap encoding mRNA.

28. A method to identify an integrin signalling complex comprising the steps of: a) preparing an extract from a cell which expresses an integrin, b) incubating said extract with a Bap protein or a Bap/p3 integrin complex, and 10 c) separating the Bap or Bap/P3 complex that bound said signalling complex from the mixture of step

29. The method of claim 28 wherein said Bap protein or said Bap/03 complex is immobilised on a solid support.

30. The use of an agent that blocks the binding of the Bap protein or a Bap 15 signalling complex to said integrin for the preparation of a medicament for u reducing the severity of a pathological state. Dated this 25th day of February 1999 4• COR THERAPEUTICS, INC Patent Attorneys for the Applicant: S'"st F B RICE CO c t 4 o• 4 1 444